RxDoctor Payments DataLook up a doctor →

Kent Smalley, MD

Neuromusculoskeletal Medicine & OMM · Edmond, OKNPI 1043265770

Payments from drug & device makers

$142,221in general payments, 2019–2025

Across 571 payments — averaging $249.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$66K
  • Avanir Pharmaceuticals, Inc.$29K
  • Acadia Pharmaceuticals Inc$26K
  • Genentech, Inc.$11K
  • AbbVie$3K
  • Eisai Inc.$1K
  • plus $7K from 39 others
$1,607in research payments, 2019–2025

Across 4 payments — averaging $401.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few neuromusculoskeletal medicine & omm providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$75,778
Medicare patients
112
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromusculoskeletal medicine & omm in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →